Redx Pharma Plc (LON:REDX) Insider Purchases £10,350 in Stock

Redx Pharma Plc (LON:REDX) insider Lisa Anson acquired 115,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The shares were acquired at an average cost of GBX 9 ($0.11) per share, with a total value of £10,350 ($12,884.35).

Lisa Anson also recently made the following trade(s):

• On Thursday, April 11th, Lisa Anson acquired 399,000 shares of Redx Pharma stock. The shares were acquired at an average cost of GBX 8 ($0.10) per share, with a total value of £31,920 ($39,736.09).

Redx Pharma Stock Up 22.7 %

Shares of LON:REDX opened at GBX 13.50 ($0.17) on Thursday. The business has a 50-day moving average price of GBX 16.75 and a 200 day moving average price of GBX 21.11. The company has a current ratio of 1.11, a quick ratio of 1.93 and a debt-to-equity ratio of 527.00. The company has a market capitalization of £52.51 million, a price-to-earnings ratio of -130.00 and a beta of -0.53. Redx Pharma Plc has a 12-month low of GBX 4 ($0.05) and a 12-month high of GBX 37.90 ($0.47).

About Redx Pharma

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.